[
    "{\"step_by_step_thinking\": \"Niraparib is a PARP inhibitor that has been studied for use in ovarian cancer. According to the documents, it has been approved for use in the maintenance treatment of ovarian cancer regardless of biomarker status. Clinical trials such as PRIMA, NOVA, AVANOVA2, and QUADRA have shown its effectiveness in treating ovarian cancer. It has been found to significantly improve progression-free survival in patients with ovarian cancer. Therefore, based on these documents, Niraparib is effective for ovarian cancer.\", \"answer_choice\": \"A\"}"
]